Group items tagged

A fourth dose of Covid-19 vaccine is not needed at present, as latest data shows first booster provides high levels of protection against Omicron variant among older adults, says the Joint Committee on Vaccination and Immunisation (JCVI). After analysing latest data from the UK Health Security Agency (UKHSA), JCVI said: "There is no immediate need to introduce a second booster dose, or fourth jab, to the most vulnerable". Data from UKSHA revealed that single booster dose provides around 90 per cent protection against hospitalisation to those aged 65 and over, even after three months of jab. However, protection against mild symptomatic infection is short-lived and drops to around 30 per cent by about three months. The study, which looked at booster doses in those aged over 65, showed that with two vaccine doses, protection against the infection drops to around 70 per cent after three months and to 50 per cent after six months.

The Department of Health and Social Care (DHSC) has suggested Estradiol patch as an alternative for patients who use 1 pump of Oestrogel daily. DHSC has updated Annex A of SSP022 and SSP023 for Oestrogel Pump-Pack 0.06 per cent gel to include a dose conversion to a specific alternative Estradiol patch. Previously, only dose conversions for patients using 2 to 4 pumps daily were included in Annex A of SSP022 and SSP023. Separately, the supporting guidance for three SSPs which allow quantity restriction have been updated to reflect the requirement to endorse the reduced quantity supplied in accordance with these SSPs. SSP019 - Oestrogel pump-pack 0.06% gel SSP020 - Ovestin 1mg cream SSP021 - Premique low dose 0.3mg/1.5mg modified release tablets "When endorsing an SSP for a reduced quantity, contractors must ensure that the correct SSP number is endorsed along with the product name and the reduced quantity supplied in accordance with the SSP," said PSNC.

NHS chief executive Amanda Pritchard joined over 17 million people in England by taking her Covid-19 booster dose on Monday (December 6) whilst encouraging people to take their top-up jab. The NHS boss got a dose in each arm as she also received her flu vaccine from pharmacist Bhaveen Patel at the Junction Pharmacy in Brixton. Pritchard later posted a video on Twitter, thanking the team in the south London community pharmacy. Ahead of the first anniversary of the NHS delivering the first Covid-19 vaccine in the world on Wednesday (December 8), Pritchard thanked the "incredible efforts" of NHS staff and volunteers who worked hard to protect millions of people. Almost 100 million jabs have been delivered in England since December 8, 2020, including over 17 million booster vaccines. Expressing her delight after taking the booster dose, Pritchard said: "The booster jab was quick, easy and I now have extra protection against the virus."

British scientists said on Thursday (December 30) they would be studying whether higher doses of a cheap and widely used steroid called dexamethasone could work better for patients with severe Covid-19 compared to the standard low doses. Last year, the same scientists conducting the large trial, dubbed RECOVERY, showed that dexamethasone was able to save the lives of Covid-19 patients in what was called a "major breakthrough" in the coronavirus pandemic. They had found that a 6 mg daily dose of dexamethasone, which is used to reduce inflammation in diseases such as arthritis, cut death rates by around a third among the most severely ill Covid-19 patients in hospitals. "Given how quickly the Omicron variant is spreading, we can expect to see patients admitted to hospital with severe Covid-19 for a while to come," said Peter Horby, an Oxford University professor co-leading the trial.

Covid-19 booster jab can now be administered sooner than six months after the second dose to certain vulnerable people as guideline in the UK Health Security Agency (UKHSA) Green Book has been updated. With the change in the guidance, care home residents who have been given their second vaccine dose at different times will be able to be jabbed in the same session, as long as it has been at least five months since their last dose. It may also help with other vulnerable groups, such as housebound patients to have their flu and Covid-19 vaccines at the same time. The move will also benefit those who are about to receive immunosuppressive treatment as they can get the booster from a minimum of four months after their second dose. Health secretary Sajid Javid said: "This updated guidance will ensure healthcare professionals have the necessary flexibility in the booster programme, allowing more vulnerable people to be vaccinated where it makes operational sense to do so." Vaccines minister Maggie Throup also encouraged eligible people to book their booster jab and secure protection.

The government announced today (November 19) that it would add booster shots to the Covid-19 pass for outbound international travel, though it added they would not be added to the domestic pass at this time. The Department of Health and Social Care said travellers who have had a booster or a third dose would be able to demonstrate their vaccine status through the NHS Covid Pass from today. The addition will enable those who have had their booster or third dose to travel to countries including Israel, Croatia and Austria who have already introduced a time limit for the Covid-19 vaccine to be valid for quarantine free travel. Booster and third doses will not be added to the domestic 'Covid Pass' as it is not a current requirement for individuals to receive booster doses to qualify as fully vaccinated. A booster is not necessary to travel into England.

Amgen's experimental obesity drug demonstrated promising durability trends in an early trial, paving the way for a larger mid-stage study early next year, company officials said ahead of a data presentation on Saturday (December 3). The small Phase I trial found that patients maintained their weight loss for 70 days after receiving the highest tested dose of the injected drug, currently known as AMG133. Amgen shares have gained about 5% since the company said on Nov. 7 that 12 weeks of trial treatment at the highest monthly dose of AMG133 resulted in mean weight loss of 14.5%. At 150 days after the last dose, maintained weight loss had dropped to 11.2% below original weight at the start of the trial, according to findings detailed at a meeting of World Congress of Insulin Resistance, Diabetes and Cardiovascular Disease in Los Angeles. Patients treated with AMG133 did have side effects including nausea and vomiting, but most cases were mild and resolved within a couple of days after the first dose, Amgen said.

The Medicines and Healthcare products Regulatory Agency (MHRA) on Tuesday authorised a Covid-19 vaccine for infants as young as six months, opening the door for vaccinating the country's youngest children once the UK's Joint Committee on Vaccination and Immunisation (JCVI) agrees. The regulator authorised the vaccine - made by Pfizer and BioNTech - for children aged six months to four years old, after it was deemed safe and effective based on an ongoing clinical trial involving 4,526 participants. Whether the vaccine is eventually deployed in this age group depends on a recommendation from the JCVI, which advises UK health departments on which shots should be used as part of the national vaccination programme. The vaccine is tailored for use in this age group - it is a lower dose version than the one used in children aged five to 11 years. It is given as three injections in the upper arm, with the first two doses given three weeks apart, followed by a third dose administered at least two months after the second dose.

Health authorities in India have said that Biological E's Covid-19 vaccine Corbevax can be administered as a booster dose in people who have taken the country's other two main shots, Covaxin and AstraZeneca's Covishield, from Friday (Aug 12). Corbevax will be available to over 18s as precautionary booster six months after a second dose, the health ministry said in an August 8 letter to state authorities. Covishield is produced for the Indian market by the Serum Institute of India under licence from AstraZeneca, while Bharat Biotech makes Covaxin. India has so far administered more than 2 billion Covid vaccine shots, including 113 million boosters, all of which have so far been of the same vaccine as the recipient's first two doses. The government says about 89 per cent of Indians above the age of 12 have had two doses.

Rilutek 50Mg Tablet Indian Suppliers , This medication is employed to treat an explicit form of nerve unwellness known as amyotrophic lateral pathology (ALS, conjointly normally known as Lou Gehrig's disease). Riluzole helps to bog down the worsening of this unwellness and prolong survival. However, it's not a cure for ALS, and it doesn't reverse nerve injury or muscle weakness. We are leading suppliers & exporters of "Rilutek 50Mg" in China, Russia, Hongkong, Bulgaria, Romania, India.We're largest suppliers of Aventis medicines & provide you the best price on Rilutek 50Mg. The lowest price sellers, suppliers, distributors & Exporters from Delhi. For more info please contact us. Rilutek 50Mg Tablet Indian Suppliers Rilutek 50Mg Suppliers India Rilutek 50Mg Riluzole is believed to figure by protective the nerves within the brain and neural structure from an excessive amount of a natural substance known as salt which will be a part of the reason behind nerve injury. RILUTEK (riluzole) may be a member of the benzothiazole category. The chemical designation for riluzole is 2-amino-6-(trifluoromethoxy) benzothiazole. Its chemical formula is C8H5F3N2OS, and its relative molecular mass is 234.2. RILUTEK may be a white to slightly yellow powder that's terribly soluble in dimethylformamide, dimethylsulfoxide, and methanol; freely soluble in dichloromethane; meagrely soluble in zero.1 N HCl; and extremely slightly soluble in water and in zero.1 N NaOH. Each film-coated Tablet for oral use contains 50 mg of riluzole and also the following inactive ingredients: anhydrous dibasic inorganic phosphate, mixture silica, croscarmellose atomic number 11, hypromellose, Mg stearate, crystalline polysaccharide, synthetic resin glycol, and titanium oxide. If you're mistreatment the liquid type of this medication, gently shake the bottle for a minimum of thirty seconds before use. Rigorously live the dose employing a special mensuration device/spoon. Don't use a

As the government today (November 15) announced plans to expand Britain's booster programme for Covid-19 vaccinations to cover all adults aged over 40, NHS Confederation welcomed the move. The announcement follows the Joint Committee on Vaccination and Immunisation (JCVI) statement that all healthy adults aged 40-49 should be offered a booster, six months after their second dose, and that 16 and 17 year olds should be invited to have a second dose. Accepting the JCVI's advice, health and social care secretary Sajid Javid said: "All 4 parts of the UK intend to follow the JCVI's advice. "We know immunity to Covid-19 begins to wane after 6 months and new data published today shows a third dose boosts protection against symptomatic infection to more than 90% - this highlights just how important it is that everyone eligible gets their top-up jabs as soon as possible."

Covid-19 vaccines made by Pfizer and Moderna that use mRNA technology provide the biggest boost to antibody levels when given 10-12 weeks after the second dose, a new study has found. The "COV-Boost" study was cited by UK officials when they announced that Pfizer and Moderna were preferred for use in the country's booster campaign, but the data has only been made publicly available now. The study found that six out of the seven boosters examined enhanced immunity after initial vaccination with Pfizer-BioNTech's vaccine, while all seven increased immunity when given after two doses of AstraZeneca's vaccine. "A third dose will be effective for many of the vaccines we've tested and in many different combinations," Professor Saul Faust, an immunologist at the University of Southampton and the trial's lead, told the media.

We cannot deny the benefits and uses of regenerative medicines as they have been so in demand in recent times. One such effective medicine with a lot of potential health benefits is BPS-157. The peptide is thought to be extremely beneficial for those struggling with various neurological or health issues. Another medicine with the same beneficial effects is the Semax peptide. Well, the benefits of both these peptide-based medicines and their other aspects will be discussed in detail in this blog along with answering your question about the BPC-157 buy, Semax effects, and polypeptide. ALL ABOUT BPC-157: BPC-157, a pentadecapeptide consisting of 15 amino acids, is a synthetic peptide that is known for its positive effects on the human body. The peptide is derived from human gastric juice. A protein is present in the human gastric juice through which this peptide is derived and synthesized. It is called a Body Protection Protein as it exerts several therapeutic effects on the human body. Not only have health benefits or therapeutic effects, the peptide has healing and regeneration powers. It also helps in the preventing formation of gastric ulcers. This peptide is of great interest to researchers due to its numerous positive effects and benefits. DOSING LEVELS OF BPC-157: Not much about the dosing levels of BPC-157 has been researched yet but always try to concern the relevant persons before taking the medicine. The dosage of BPC-157 depends on the health and body conditions of the person taking it along with other related factors.

National Institute of Health and Care Excellence (NICE) has not recommended 'Tirzepatide', also known as Mounjaro, developed by Eli Lilly, in its draft guidance issued on Tuesday (27 June) for treating type 2 diabetes in adults alongside diet and exercise. The independent NICE committee recognised the importance of new treatment options given that fewer than two-thirds of the adults with type 2 diabetes have adequate glucose control when using current treatment options. Evidence submitted to the committee from clinical trials showed the use of tirzepatide at any dose resulted in better glucose control and lower weight compared with semaglutide or insulin therapy. The weight reduction was more pronounced with higher doses of tirzepatide, while the effect on glucose levels seemed less dose-dependent. Similar effects were observed against all GLP-1 receptor agonists in company's network meta-analysis, but this was uncertain. The committee have asked the company to provide more data to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.

To help manage the ongoing supply disruptions, the health regulators have extended to 28 October 2022, serious shortage protocols (SSPs) for 12 of the 13 hormone replacement therapies (HRT). "The only HRT SSP set to expire on 29 July 2022 is for SSP021 Premique low dose 0.3mg/1.5mg modified-release tablets. After 29 July, there will be no need to restrict quantities of Premique tablets as its supply situation has now stabilised," said PSNC. In addition, the dose equivalence advice and endorsement guidance for SSP024 and SSP025 have been updated. SSP024 and SSP025 have been updated by DHSC to provide greater clarity to pharmacists on the dose equivalences to determine the appropriate quantity to supply. Pharmacists are asked to refer to the latest SSP versions and endorsement guidance published on NHSBSA's website.

A new study has revealed that the risk of death from COVID-19 decreases significantly after vaccination, but this protection diminishes after six months, providing evidence for continued booster doses. Researchers from the UK Health Security Agency (UKHSA), who analysed more than 10 million cases of COVID-19 in adults in England between May 2020 and February 2022, found a clear association between vaccination and reduced mortality. But they also highlighted a crucial timeframe - within six months of the last vaccine dose - when Case Fatality Risk (CFR) - the proportion of cases that resulted in death - was consistently at its lowest across all age groups. After this, the protective benefit of the vaccine began to wane and CFR increased.

To curb the supply issue of HRT medicine, the government has taken a further action by issuing SSPs for Oestrogel, Ovestin cream, Lenzetto transdermal spray and Sandrena gel sachets - with appropriate alternatives. The move aims to allow community pharmacists to supply specified alternatives to the prescribed HRT products without needing to seek authorisation from the clinician who has prescribed the medicine. The regulator said that the availability of Premique Low Dose has impoved 'thanks to SSPs issued on 29 April to restrict dispensing for Oestrogel, Ovestin and Premique Low Dose to three months' supply'. "Since these measures were implemented, further deliveries of all three products have been made, with Premique Low Dose returning to good availability this week. The manufacturers of Oestrogel and Ovestin, as well as suppliers of alternative HRT products, are taking action to increase UK supply." It added, "SSPs restricting prescriptions to a maximum of three months' supply will also be issued for substitute products, as a precautionary measure to ensure the supply of those substitutes is maintained."

A change in medication can benefit patients on blood pressure-lowering therapies significantly more than increasing the dose of their current medication. A recent study from Uppsala University that was published in the Journal of the American Medical Association (JAMA) demonstrates this. In this study, four different blood pressure-lowering medications were tested out on 280 individuals over the course of a year. "The effect of a change of medication can be twice as great as the effect of doubling the dose of the patient's current medication. It was clear in our study that certain patients achieved lower blood pressure from one drug than from another. This effect is large enough to be clinically relevant," said Johan Sundstrom, cardiologist and Professor of Epidemiology at Uppsala University, who is the first author of the study. Most Swedes develop high blood pressure sooner or later; more than two million Swedes have high blood pressure at the present time. Only a fifth of them have managed to bring their blood pressure under control through drug therapy, and some studies suggest that only half of them take their blood pressure medication as intended. Could this be because the efficacy and side-effects of the drugs differ from individual to individual?

Britain will offer a Covid-19 booster shot to all adults and could halve the dose interval for booster jabs from six to three months in a bid to accelerate its vaccination programme amid concern over the new Omicron coronavirus variant, as number of new cases found in the country rise. The move, backed by a scientific advisory body and Health Secretary Sajid Javid, comes as ministers scramble to react swiftly to the new variant, which was first detected in South Africa. Prime minister Boris Johnson has responded to the emergence of Omicron by making mask-wearing compulsory in shops and on public transport in England. Until now, only adults in the UK aged 40 and above were eligible for a booster dose six months after their last. But that timeframe will now be halved to three months, alongside the programme's expansion to all over-18s, with priority given to older people. "These measures will protect more people, more quickly and make us better protected as a nation," Javid told MPs.

Pirfenex 200Mg Tablets Suppliers India, Pirfenex® is a famous product on international market for pirfenidone, an oral medication used for the treatment of idiopathic pulmonary fibrosis (IPF). Each pack coated tablet pirfenidone 200 Mg. We are leading suppliers & exporters of "Pirfenex 200 Mg Cipla Pirfenidone Tablet" in China, Russia, Hongkong, Bulgaria, Romania, India. As we are a largest suppliers and exporters of Cipla medicines & provide you the best price on Pirfenex 200 Mg Cipla Pirfenidone Tablet. The lowest price Sellers, Suppliers, Distributors & Exporters from Delhi. For more info please contact Us. Buy Online Pirfenex 200Mg Cipla Pirfenidone Tablet in Russia-China-India Pirfenex tablets suppliers India Pirfenex 200Mg Pirfenex200 Mg Cipla Pirfenidone Tablet include chemical salt Pirfenidone 200 Mg. Pirfenex comes in 200 Mg Stength. Pirfenex available in 30 tablets pack. Pirfenex is manufactured by Cipla. Of these, the bleomycin model is the most widely used model of pulmonary fibrosis. Medicine Detail: Brand Name: Pirfenex Chemical salt: Pirfenidone Strength: 200 mg Packing: 30 Tablets Form: Tablet Manufactured: Cipla Ltd Pirfenex200mg Pirfenidone Tablet is an antifibrotic agent and used to treat gentle cases of a lung disease namely idiopathic pulmonary fibrosis. While the exact working of this medication is not known. On utilizing this medication you will expertise aspect effects like muscle pain, sneezing, dizziness, reduced craving, sharp weight loss, issue with sleeping, heartburn, acidity, amendment in style, weakness, fatigue, headache, runny nose, indigestion, diarrhea, nausea, vomiting, rash and redness. If you face any hypersensitivity or adverse reactions request the assistance of your health care supplier directly. Before using this drug give notice to your doctor if: you're allergic to any of the ingredients contained at intervals Pirfenex200mg tablets, you've got liver /kidney issues, you've got the other allergies,